Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder.

Clinical Trial Description

The primary goal of this study is to examine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder (BD II). Fourteen participants, ages 30 to 65 with clinically diagnosed BD II with active depression, in active outpatient mental health treatment, and who meet all other inclusion and exclusion criteria at screening will be enrolled. After baseline assessments, participants will engage in preparatory visits with trained facilitators, followed by an initial drug administration of oral psilocybin,supervised by the facilitators and a clinician who will conduct safety monitoring throughout. Participants will complete assessment and integration sessions with the facilitators subsequently in order to help process the experience. Participants who tolerated the first dosage may be asked to complete a second psilocybin dosing session, involving the same preparation, procedures, integration, and supervision as the first. Primary outcome measures will assess safety, tolerability, and feasibility of study procedures. Efficacy will be measured by change in depression as measured by the MADRS three weeks after the final psilocybin administration. Exploratory outcome measures will assess changes in sleep, quality of life, and therapeutic engagement. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05065294
Study type Interventional
Source University of California, San Francisco
Contact Kimberly Sakai
Phone 415-221-4810
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date November 2021
Completion date September 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Not yet recruiting NCT04561622 - Emotional Proactive Processing in Bipolar Disorder
Completed NCT00761761 - Sensoril(Ashwaganhda)for Bipolar Disorder Phase 3
Not yet recruiting NCT05064319 - Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders Phase 2
Completed NCT03334721 - Gabapentin for Bipolar & Cannabis Use Disorders Phase 2
Recruiting NCT03484494 - Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression N/A
Recruiting NCT04211428 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder
Completed NCT03822416 - Treating Smokers With Mental Illness Phase 2
Completed NCT01588457 - Sequential Multiple Assignment Treatment for Bipolar Disorder Phase 4
Active, not recruiting NCT03156504 - The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. Phase 1
Terminated NCT02491307 - Behavioral Health Study N/A
Completed NCT02593643 - Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression. Early Phase 1
Completed NCT03810703 - Differential Responses to Drugs and Sweet Tastes Phase 1
Completed NCT01075295 - Prevention of Weight Gain in Early Psychoses N/A
Completed NCT00237666 - Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression Phase 4
Completed NCT01731119 - Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents Phase 2
Completed NCT00411463 - Psychotherapy for Bipolar II Depression, Pilot Study, Phase II Phase 2/Phase 3
Completed NCT00186043 - Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II Phase 4
Recruiting NCT04035798 - add-on Low Dose Memantine in Middle-to-old Aged Bipolar II Disorder Patients Phase 2/Phase 3
Recruiting NCT03603561 - Continuous Theta Burst Stimulation as an add-on Treatment for Bipolar Depression N/A